Literature DB >> 12094395

[Pericarditis as the initial manifestation of retroperitoneal fibrosis--a case report].

Martina Baur1, W Hulla, H Kienzer, M Klimpfinger, Ch Dittrich.   

Abstract

HISTORY AND CLINICAL
FINDINGS: A 70-year-old patient with invasive ductal breast cancer underwent conserving surgery of the right breast and right axillary dissection as well as postoperative irradiation therapy. Five months later, she presented with dyspnoea and progressive weakness. INVESTIGATIONS: Clinically, the patient showed anasarca and petechial hemorrhages, laboratory tests revealed thrombopenia, hepatic dysfunction, radiologic investigations showed enlargement of the liver and spleen, effusions of the pleura and pericardium, and ascite. Echocardiography showed pericardial effusion without cardiac tamponade. TREATMENT AND COURSE: Despite supportive therapy the patient's performance status deteriorated significantly, the diagnosis of the underlying disease could not be established, the patient died with the clinical signs of cardiovascular failure. Autopsy revealed progressive retroperitoneal fibrosis with systemic involvement of pleura, pericardium, epicardium, myocardium, lungs, and kidneys and pericarditis. Retrospectively clinical symptoms were interpreted as right heart insufficiency due to pericardial effusion.
CONCLUSION: This case report reminds of occurrence of manyfold clinic manifestations of retroperitoneal fibrosis in dependence of particular organic involvement and that retroperitoneal fibrosis represents a differential diagnosis.

Entities:  

Mesh:

Year:  2002        PMID: 12094395     DOI: 10.1046/j.1563-258x.2002.02031.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  1 in total

1.  IgG4-related sclerosing disease involving the superior vena cava and the atrial septum of the heart.

Authors:  Changho Song; Myoung Ju Koh; Yong-Nam Yoon; Boyoung Joung; Se Hoon Kim
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.